<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26826">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02011815</url>
  </required_header>
  <id_info>
    <org_study_id>BreastCA_circa_mech</org_study_id>
    <nct_id>NCT02011815</nct_id>
  </id_info>
  <brief_title>Exploring Biological Linkage Between Circadian Disruption and Cancer Progression</brief_title>
  <official_title>A Prospective Study of Exploring Possible Biological Linkage Between Circadian Disruption and Cancer Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the possible association between the circadian
      disruption and cancer progression. The biological markers that are assumed to bridge this
      association are measured and analyzed.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>3 years (and more) after recruitment</time_frame>
    <safety_issue>No</safety_issue>
    <description>The data on survival will be verified via Statistics Korea.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years (and more) after recruitment</time_frame>
    <safety_issue>No</safety_issue>
    <description>The data progression-free survival will be done by reviewing patients' medical record.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Circadian disruption</measure>
    <time_frame>Baseline, after 1 month, after 6 month, after 12 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Morningness-Eveningness Questionnaire and Munich Chronotype Questionnaire will be used during assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective sleep cycle measures</measure>
    <time_frame>Baseline, after 1 month, after 6 month, after 12 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>The assessment will be performed by using actigraph and sleep diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiological measures</measure>
    <time_frame>Baseline, after 1 month, after 6 month, after 12 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>The measures include blood pressure, body temperature, skin conductance, breathing pattern, and Electroencephalography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality measures</measure>
    <time_frame>Baseline, after 1 month, after 6 month, after 12 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>The measurements will be performed using Epworth sleepiness scale, Pittsburgh Sleep Quality Index, and Insomnia Severity Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life measure</measure>
    <time_frame>Baseline, after 1 month, after 6 month, after 12 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>The measurement will be performed using M.D. Anderson Symptom Inventory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer related Fatigue</measure>
    <time_frame>Baseline, after 1 month, after 6 month, after 12 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fatigue severity scale will be used during the assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distress related measure</measure>
    <time_frame>Baseline, after 1 month, after 6 month, after 12 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hospital Anxiety and Depression Scale will be used during the assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Posttraumatic Stress-related symptom measure</measure>
    <time_frame>Baseline, after 1 month, after 6 month, after 12 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Impact of Event Scale-revised will be used to categorize and quantify Posttraumatic stress-related symptom in cancer patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menopausal symptom measure</measure>
    <time_frame>Baseline, after 1 month, after 6 month, after 12 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Menopause Rating Scale will be used during the assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Personality measure</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Temperament and Character Inventory will be used to examine the personality factor in each participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic polymorphism</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Variable Number Tandem Repeat and Single Nucleotide Polymorphism of circadian-rhythm related genes will be examined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epigenetic Change</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>The methylation specific Polymerase Chain Reaction technique will be used to explore methylation patterns in circadian clock gene or in a global gene level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortisol level</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Salivary cortisol level will be measured multiple times at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Melatonin</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Salivary or Urine melatonin level will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>The various inflammation markers will be measured from blood sample.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">236</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Breast cancer</arm_group_label>
    <description>Diagnosed breast cancer patients who are getting chemotherapy for the first time.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, serum Saliva Urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        University (Tertiary) hospital, oncology clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-70

          -  Breast cancer patients who are getting chemotherapy for the first time in life

          -  Patients are either having stage 4 cancer or starting neoadjuvant chemotherapy.

          -  Patient have signed on the informed consent, and well understood the objective and
             procedure of this study

        Exclusion Criteria:

          -  Patients already have received chemotherapy

          -  Patient had another cancer (except thyroid cancer) within 5 years

          -  Patient with severe medical condition

          -  Patient had taken psychiatric medication more than 1 month in life

          -  Patient worked the night shift for more than 1 month in 6 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bong-Jin Hahm, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dooyoung Y Jung, M.D.</last_name>
    <phone>82220723767</phone>
    <email>dooyoung@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <zip>140-013</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dooyoung Y Jung, M.D.</last_name>
      <phone>82220723767</phone>
      <email>dooyoung@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Bong-Jin Hahm, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dooyoung Y Jung, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.snuh.org/</url>
    <description>study site webpage</description>
  </link>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 12, 2013</lastchanged_date>
  <firstreceived_date>December 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast neoplasms</keyword>
  <keyword>Circadian rhythm</keyword>
  <keyword>sleep</keyword>
  <keyword>survival</keyword>
  <keyword>distress</keyword>
  <keyword>anxiety</keyword>
  <keyword>depression</keyword>
  <keyword>quality of life</keyword>
  <keyword>actigraph</keyword>
  <keyword>fatigue</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplastic Processes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
